Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
371 Leser
Artikel bewerten:
(2)

Veeva Systems: Servier to Adopt Veeva RIM to Streamline and Advance its Global Regulatory Operations

Leading biopharma to unify global regulatory operations on a single platform to speed submissions for new patient therapies

BARCELONA, Spain, Feb. 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Servier will adopt Veeva RIM to unify its global regulatory operations. By bringing regulatory processes together on a single platform, Servier can improve visibility, submission speed, and compliance.

Veeva Systems

"Unifying regulatory data, documents, and processes on Veeva RIM will help Servier streamline operations and accelerate patient access to new medicines," said Alexandra Pearce, global head, worldwide regulatory affairs at Servier. "With Veeva, we have a reliable partner to help us scale and connect teams while driving better regulatory oversight and reducing time to submission."

With headquarters in France, Servier is an independent, global pharmaceutical leader in delivering cardio-metabolism, venous diseases, and oncology therapies. Veeva RIM is a unified platform of regulatory applications, including Veeva Registrations, Veeva Submissions, Veeva Submissions Publishing, and Veeva Submissions Archive, offering biopharmas like Servier real-time visibility throughout the regulatory process. With Veeva RIM, Servier has a solution that enables quick adaptation to evolving EU regulatory demands. Veeva is partnering with Servier to roll out the technology across Europe, and globally, streamlining regulatory operations to reduce time to market for new therapies.

"Servier is showing true digital leadership in its approach to transforming its regulatory operations," said Paul Attridge, vice president of Veeva RIM strategy at Veeva Europe. "With our successful track record implementing Veeva RIM, Veeva's French and global teams look forward to helping Servier advance its regulatory management and deliver medicines to patients more quickly."

Veeva RIM is part of Veeva Development Cloud, the technology foundation for product development across clinical, regulatory, quality, and safety.

Additional Information
For more on Veeva RIM, visit: veeva.com/eu/VeevaRIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/servier-to-adopt-veeva-rim-to-streamline-and-advance-its-global-regulatory-operations-302366729.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.